Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Icon Wealth Advisors LLC

Icon Wealth Advisors LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 3,955.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 174,040 shares of the medical research company’s stock after purchasing an additional 169,748 shares during the quarter. Icon Wealth Advisors LLC’s holdings in Amgen were worth $56,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Lazard Asset Management LLC lifted its holdings in shares of Amgen by 4.4% in the first quarter. Lazard Asset Management LLC now owns 31,841 shares of the medical research company’s stock valued at $9,051,000 after purchasing an additional 1,353 shares in the last quarter. Waverly Advisors LLC lifted its stake in shares of Amgen by 54.4% in the first quarter. Waverly Advisors LLC now owns 9,628 shares of the medical research company’s stock valued at $2,737,000 after buying an additional 3,393 shares during the period. Bayesian Capital Management LP bought a new stake in shares of Amgen in the first quarter valued at about $2,082,000. Kennedy Capital Management LLC bought a new position in Amgen during the first quarter worth about $3,240,000. Finally, Oxford Wealth Group LLC acquired a new stake in shares of Amgen during the first quarter worth approximately $299,000. 76.50% of the stock is owned by institutional investors.

Amgen Stock Performance

Shares of Amgen stock opened at $294.53 on Monday. The company has a market capitalization of $158.32 billion, a PE ratio of 37.71, a P/E/G ratio of 2.59 and a beta of 0.60. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The company has a 50-day simple moving average of $316.52 and a two-hundred day simple moving average of $318.18. Amgen Inc. has a one year low of $260.68 and a one year high of $346.85.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same quarter in the prior year, the firm posted $4.96 EPS. The business’s quarterly revenue was up 23.2% compared to the same quarter last year. Research analysts expect that Amgen Inc. will post 19.52 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.06%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Analyst Ratings Changes

A number of analysts recently weighed in on AMGN shares. TD Cowen raised their price target on shares of Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a report on Monday, October 21st. UBS Group cut their price objective on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research report on Thursday, October 31st. Jefferies Financial Group reissued a “buy” rating and set a $380.00 price target on shares of Amgen in a research report on Tuesday, November 12th. Cantor Fitzgerald reissued an “overweight” rating and set a $405.00 price target on shares of Amgen in a research report on Tuesday, October 22nd. Finally, Robert W. Baird restated an “underperform” rating and set a $215.00 price objective on shares of Amgen in a research note on Wednesday, September 25th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $333.57.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.